Skip to main content
Premium Trial:

Request an Annual Quote

New York Gives Green Light to Navigenics' Genetic Testing

NEW YORK (GenomeWeb News) – Navigenics has received a license to offer its personal genomics services to residents of New York State, the firm said today.

The New York State Department of Health has granted Navigenics a clinical laboratory permit and has said that the company may offer its Health Compass service to state residents.

The approval will enable the company to process saliva samples originating in New York using its CLIA-certified lab.

Specifically, the permit means that the state's Clinical Laboratory Evaluation Program found that the company's validation data is acceptable and that it has clarified the regulatory framework that covers such companies.

New York said last summer that it planned to regulate companies offering educational information about genetic risk as clinical laboratories, although direct-to-consumer firms had argued that their services provided different types of information than regular lab tests.

"Our priority is to ensure that New York residents whose physicians order services from Navigenics do so within the assurance of quality and technical reliability that our scrutiny provides, and we are satisfied that Navigenics has met the State's requirements for approval," Michele Caggana, head of the Genetic Testing Section of the Clinical Laboratory Reference System, said in a statement.

"The State’s licensing inspection program and regulatory framework are extremely rigorous," Navigenics' Laboratory Director Douglass Harrington said in a statement.

The company said its testing service will be available to New York residents this year.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.